Obstetric Hemorrhage Medications

Learning objectives

After completing this chapter, you should be able to identify the likely cause of obstetric hemorrhage; select uterotonic therapy using contraindication-based reasoning; explain the role and timing of tranexamic acid; anticipate blood-product, fibrinogen, calcium, and warming needs; recognize when medication-only treatment is failing; safely continue hemorrhage-control devices and infusions during transport; and coordinate rapid escalation to operative or interventional care.

Opening transport scenario

A 34-year-old patient has persistent bleeding after a vaginal birth. The uterus is enlarged and boggy. Oxytocin is infusing, quantified blood loss has passed 1,200 mL, heart rate is 126/min, blood pressure is 104/66 mm Hg, and fibrinogen is pending. She has severe asthma and a history of gestational hypertension. The team must choose additional medication without worsening bronchospasm or hypertension, decide whether tranexamic acid remains within its treatment window, and prepare for rapid progression to coagulopathy and shock during transport.

1. Hemorrhage treatment is a system, not a single drug

Postpartum hemorrhage is commonly organized by the four Ts: tone, trauma, tissue, and thrombin. Uterotonics treat uterine atony—the most common cause—but they will not repair a cervical laceration, remove retained placenta, reverse uterine inversion, or definitively correct disseminated intravascular coagulation. Medication selection must occur at the same time as source identification, resuscitation, blood-product activation, and escalation to procedural control.

2. Oxytocin

Oxytocin is the usual first-line uterotonic for prevention and treatment of uterine atony. It increases rhythmic uterine contraction and is commonly continued as an infusion after an initial dose. Concentrations and infusion rates vary widely, so transport clinicians must verify the exact dose already given, bag concentration, pump rate, remaining volume, and whether additional bolus dosing is permitted.

• Major transport concern: a rapid IV bolus can produce hypotension, tachycardia, flushing, and hemodynamic instability.
• Infusion safety: trace tubing from patient to pump, identify the dedicated line, verify compatibility, and protect against accidental free flow during stretcher transfer.
• Failure signal: persistent bleeding despite a firming uterus suggests trauma, retained tissue, or coagulopathy rather than simply “not enough oxytocin.”

3. Methylergonovine

Methylergonovine produces sustained uterine contraction through serotonergic and alpha-adrenergic effects. A common educational dose is 0.2 mg intramuscularly, repeated according to protocol. Its vasoconstrictive properties make medication history and blood-pressure assessment essential.

Transport monitoring includes serial blood pressure, chest symptoms, neurologic status, ECG when indicated, uterine tone, and bleeding. Do not select methylergonovine merely because it is the next drug in a memorized sequence; select it because the patient has no important contraindication.

4. Carboprost

Carboprost is a prostaglandin F2-alpha analogue that produces strong uterine contraction. A common educational dose is 250 micrograms intramuscularly or intramyometrially, repeated at protocol-defined intervals to a maximum cumulative dose. Bronchoconstriction is the major transport concern.

• Avoid or use extreme caution in patients with asthma or active bronchospasm.
• Monitor for wheezing, increased airway resistance, hypoxemia, vomiting, diarrhea, fever, and hypertension.
• Have bronchodilator therapy and airway support immediately available when clinically appropriate.
• Do not attribute respiratory deterioration to anxiety after carboprost until bronchospasm and pulmonary edema have been assessed.

5. Misoprostol

Misoprostol is a prostaglandin E1 analogue that can be administered by several routes. It is useful when injectable uterotonics are unavailable or as adjunctive therapy, but onset and absorption vary by route. Common adverse effects include shivering, fever, nausea, vomiting, and diarrhea. High fever after misoprostol may mimic infection; interpret the timing and the full clinical picture.

6. Tranexamic acid

Tranexamic acid (TXA) inhibits fibrinolysis and is used as an adjunct to standard postpartum-hemorrhage care. Benefit is greatest when it is administered early—ideally as soon as hemorrhage is recognized and within three hours of birth. A common regimen is 1 g IV over approximately 10 minutes, with a second 1 g dose considered if bleeding continues after 30 minutes or restarts within 24 hours, according to protocol.

• TXA does not contract the uterus and does not replace source control.
• Administering it too rapidly can cause hypotension.
• Verify the time of birth, time hemorrhage was recognized, prior TXA dose, and time of administration.
• Use caution in active intravascular clotting or a clear contraindication; ordinary concern about venous thromboembolism risk should be discussed with the treating team rather than used as an automatic reason to withhold indicated treatment.
• Continue mechanical, surgical, transfusion, and uterotonic treatment as indicated.

7. Blood products and massive transfusion

Crystalloid does not replace oxygen-carrying capacity, fibrinogen, platelets, or clotting factors. When bleeding is substantial or ongoing, early activation of an obstetric massive-transfusion pathway may be safer than waiting for profound hypotension. Transport planning should identify what blood products are running, what products are available en route, and what the receiving facility can immediately provide.

Fibrinogen often falls early in severe obstetric hemorrhage. A level near or below 200 mg/dL in a bleeding obstetric patient should raise major concern and prompt immediate discussion of fibrinogen replacement. Use the local laboratory’s units and the institutional hemorrhage algorithm.

8. Calcium, temperature, and the lethal cycle

Hemorrhage, hypoperfusion, hypothermia, acidosis, dilution, and hypocalcemia reinforce one another. Citrate in transfused blood binds calcium, and low ionized calcium impairs myocardial contractility and coagulation. Transport care should therefore include temperature control, calcium planning, blood warming, serial acid–base assessment, and avoidance of unnecessary crystalloid dilution.

9. Bakri balloon and JADA system during transport

Hemorrhage-control devices require more than “device present” documentation. Verify indication, placement time, securing method, tubing configuration, drainage amount, suction setting if applicable, vaginal packing, expected removal plan, and what change requires immediate escalation.

• Bakri balloon: document fill volume, drainage channel patency, vaginal bleeding around the device, and signs of displacement.
• JADA system: verify intrauterine placement, cervical seal fill, prescribed low-level vacuum, uterine response, and whether bleeding is entering the collection system.
• Do not conceal ongoing hemorrhage with absorbent padding. Quantify output and inspect beneath the patient.
• Device failure, worsening shock, suspected uterine rupture, or inability to maintain the system may require diversion to immediate operative capability.

10. Transport priorities

1. Identify the likely cause while continuing broad hemorrhage resuscitation.
2. Activate blood and surgical resources early; do not wait for a late blood-pressure collapse.
3. Choose uterotonics by contraindication, not by memorized order alone.
4. Record every dose, route, exact time, response, and adverse effect.
5. Trend quantified blood loss, uterine tone, mental status, shock index, EtCO₂ when appropriate, temperature, calcium, fibrinogen, and coagulation.
6. Secure all pumps, blood tubing, warming devices, drainage systems, and hemorrhage-control devices.
7. Define diversion criteria before departure.

11. Evolving case study

Phase 1

The patient’s uterus remains boggy despite massage and oxytocin. Because she has severe asthma and gestational hypertension with current blood pressure 156/96 mm Hg, carboprost and methylergonovine both present meaningful risk. Misoprostol is administered and TXA is started within one hour of birth.

Phase 2

Bleeding continues, heart rate rises to 138/min, temperature is 35.5°C, fibrinogen returns at 165 mg/dL, and ionized calcium is low during transfusion. The problem is no longer “which uterotonic next.” The team activates massive transfusion, requests fibrinogen replacement and calcium, increases warming, and coordinates procedural control.

Phase 3

A JADA system is placed before departure with decreasing but persistent output. During transport, blood pressure falls, mental status changes, and the collection canister fills rapidly. The original destination is 35 minutes away; a surgical obstetric center is 8 minutes away. Immediate consultation and diversion are indicated.

12. High-yield summary

• Treat the cause: uterotonics treat tone, not trauma, tissue, or thrombin.
• Oxytocin is first-line, but rapid IV bolus can cause hypotension.
• Avoid methylergonovine in hypertension or preeclampsia.
• Avoid carboprost in asthma or active bronchospasm.
• Give TXA early, ideally within three hours of birth, without delaying source control.
• Pregnancy fibrinogen is normally high; a low-normal adult value can signal severe depletion.
• Balanced blood products, fibrinogen, calcium, warming, and procedural control are part of one system.
• Hemorrhage-control devices require active monitoring and quantified output.

References

1. American College of Obstetricians and Gynecologists. Postpartum Hemorrhage. Practice Bulletin No. 183.
2. Alliance for Innovation on Maternal Health. Obstetric Hemorrhage Patient Safety Bundle and Change Package.
3. World Health Organization. Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage. 2025.
4. World Health Organization. Recommendation on tranexamic acid for the treatment of postpartum haemorrhage.
5. International Board of Specialty Certification. Maternal Fetal Transport Microcredential Candidate Handbook. Updated April 2026.